comparemela.com

Latest Breaking News On - Area lead oncology - Page 1 : comparemela.com

ESMO 2023: Janssen reveals data for intravesical delivery system

ESMO 2023: Janssen reveals data for intravesical delivery system
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Italy
Martin-vogel
Andrea-necchi
Janssen-cilag-gmb
European-society-for-medical-oncology
Scientific-institute
Janssen-pharmaceutical-companies-of-johnson
Salute-san-raffaele-university
Bacillus-calmette-gu
Pharmaceutical-companies
European-society
Medical-oncology

First Results with Erdafitinib-Releasing Intravesical

Investigational TAR-210 first-in-human results highlight the potential for local sustained release of erdafitinib with a novel intravesical delivery.

Vilaseca
Comunidad-autonoma-de-cataluna
Spain
Madrid
Belgium
Beerse
Region-flamande
Barcelona
Indianj-urol
Janssen-cilag-gmb
Janssen-pharmaceutica
Jeffrey-infante

Results from Phase 2 THOR-2 Study Showed Improved Rates of

Data from Cohort 1 of the Phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical.

Spain
Belgium
Madrid
Beerse
Region-flamande
United-kingdom
Janssen-cilag-gmb
Indianj-urol
Kiran-patel
James-wf-catto
Martin-vogel
Janssen-pharmaceutica

Johnson & Johnson : Janssen Aims to Define New Standards of Care in the Treatment of Solid Tumor Cancers with Transformative Data Planned for Presentation at ESMO -October 16, 2023 at 08:33 am EDT

News Release Media Contacts: Brian Kenney +1 215-620-0111 Suzanne Frost +1.

Janssen-cilag-gmb
Peter-lebowitz
Martin-vogel
Janssen-research-development
Global-therapeutic-area-head
Janssen-research
Area-lead-oncology
Presidential-symposium
Markets

European Approval Sought for Amivantamab Plus Chemo in EGFR Exon 20 Insertion+ NSCLC

A Type II extension of indication application seeking the approval of amivantamab in combination with carboplatin and pemetrexed for the frontline treatment of adult patients with advanced non–small cell lung cancer and activating EGFR exon 20 insertion mutations has been submitted to the European Medicines Agency.

Janssen-cilag-gmb
Martin-vogel
Kiran-patel
Janssen-research-development
European-medicines-agency-for-rybrevant
European-medicines-agency
Drug-administration
Janssen-pharmaceutical-companies-of-johnson
European-commission
Area-lead-oncology
Janssen-cilag-gmbh
Janssen-research

vimarsana © 2020. All Rights Reserved.